Trypanocide Treatment of Women Infected with Trypanosoma cruzi and Its Effect on Preventing Congenital Chagas

Diana L. Fabbro1, Emmaria Danesi2, Veronica Olivera1, Maria Olenka Codebo3, Susana Denner1, Cecilia Heredia2, Mirtha Streiger1, Sergio Sosa-Estani2,3*

1Centro de Investigaciones sobre Endemias Nacionales (CIEN) - Facultad de Bioquímica y Ciencias Biológicas- Universidad Nacional del Litoral, Santa Fe, Argentina, 2Centro Nacional de Diagnostico e Investigaciones Endemo-epidemicas, Administración Nacional de Laboratorios e Institutos de Salud (ANLIS), Buenos Aires, Argentina, 3Instituto Nacional de Parasitológia (INP), “Dr Mario Fatale Chaben”, Administración Nacional de Laboratorios e Institutos de Salud (ANLIS) Malbrán, Buenos Aires, Argentina

Introduction

The most common transmission routes of Chagas disease are vectorial, transfusional and congenital, but other routes described include oral, organ transplants, needle sharing among injecting drug users and accidents.

In recent years, significant progress has been made in the fight against triatominies, which, added to the controls implemented by blood banks, drastically reduced infections by Trypanosoma cruzi through the vectorial and transfusional routes [1].

Given the current migrations from rural areas to urban centers, this way of infection may be encountered may occur in regions considered of low or very low endemicity and even in countries where the vector is not found [2–5].

Currently, vertical transmission is considered as the source that generates the highest number of new acute infection cases [6]. However, less than 20% of children born with congenital infection due to difficulties in the health system, which fails to perform an adequate follow-up of the newborn [7,8]. As most infected children have no symptoms, the mothers feel no need for medical intervention, to which one must add the economic difficulties of traveling to the health center. The importance of early detection lies in the possibility of receiving trypanocidal therapy, which is highly effective at this stage of the infection [9–11].

The present study is based on a preliminary observation, with a limited number of cases, where it is hypothesized that trypanocidal therapy has beneficial effects in the prevention of congenital transmission of T. cruzi [12].

In chronically infected adult patients, antiparasitic treatment was recently reconsidered as useful on different levels of prevention (i.e., primary prevention by interruption of the transmission cycle, secondary prevention by preventing development of the disease, tertiary prevention by preventing progression of the disease) [13]. The trypanocide treatment in pregnant women is not indicated due to lack of evidence of complete safety for potentially...
Design

Methods

In order to corroborate the hypothesis of efficacy of the treatment in interrupting the transmission of congenital Chagas disease, the following objective was proposed: to evaluate the effect of the specific antiparasitic treatment in the prevention of congenital Chagas disease. We have analyzed also the serological and clinical evolution of mothers chronically infected with *T. cruzi* treated and untreated with trypanocidal drugs.

**Study sample**

For assessing the objective, the unit of analysis was the clinical record of the “infected mother with *T. cruzi* in chronic phase-biological child” pair. The inclusion criteria were:

- for the women: a) treated or untreated women with trypanocidal drugs who at the start of the follow-up had 2 or more reactive serological tests for infection with *T. cruzi*; b) socio-epidemiological information: date of birth; c) trypanocidal treatment information (if the case): date, dose, schedule and grade of completion.

- for the biological children of women: a) confirmed diagnosis of absence or presence of infection with *T. cruzi*, diagnosed by parasitological methods before 10 months age and/or serological methods after 9 months of age; b) socio-epidemiological information: date of birth, places where the child lived before diagnosis; c) healthcare information: whether or not he/she had received transfusions, dates and results of the first parasitological and/or serological tests that confirmed status of infection.

Regarding trypanocidal treatment, it was considered a complete treatment with benznidazole in a dose of 5 mg/kg/day administered in two times a day, during 30–60 days, or with nifurtimox in a dose of 10 mg/kg/day administered in two times a day, during 30–60 days. Tolerance to treatment was considered: i) good, if the patient had no side effects or were very slight, ii) regular, if the patient required symptomatic treatment for side effects but didn’t interrupt taking trypanocidal drugs, and iii) bad, if due to side effects it was necessary to interrupt treatment.

Women and child were only recruited if both fulfilled the inclusion criteria.

To assess serological and clinical evolution of mothers, we analyzed only those women who, fulfilling the inclusion criteria mentioned above had a serological follow-up equal to or greater than 8 years.

Serology included the following determinations for the detection of anti-*T. cruzi* antibodies: Indirect hemagglutination (IHA), indirect immunofluorescence (IIF) and enzyme immunoassay (ELISA), performed in each center with internal quality control. The centers take part of the Quality Control Program through the National Network of Laboratories which regularly submit to external quality controls performed by the National Institute of Parasitology. All results of tests obtained as secondary data from medical records or performed during the project and informed as primary were under the same quality control procedures.

Clinical controls consisted of clinical examinations and 12-lead electrocardiogram (ECG). The alterations in the ECG that were compatible with chronic Chagas cardiomyopathy (CCC) were the following: Complete Right Bundle Branch Block (RBBB); Left Anterior Fascicular Block (LAFB) in persons under 50 years of age;
frequent Ventricular Extrasystoles (fVE); Second-degree Atrioventricular Block (2°AVB); Complete Atrioventricular Block (CAVB) and electrically “silent” areas with no history of ischemic heart disease.

Data collection

Each center implemented screening through medical record (MR) review of infected women treated and untreated with trypanocidal drugs. Women who had not had children or that wasn’t possible to contact to verify this condition were excluded. Women with chronic infection who had become mothers and their children were considered eligible. Upon verification of the existing data of eligible cases, we used the following strategies: a) retrospective: with secondary data if the MR contained all the information required for inclusion; b) retrospective and prospective: if the MR lacked information for considering inclusion, we proceeded to contact the patient to collect such information, and, if necessary, to conduct studies and sampling for laboratory testing. In the last case, we considered both pre-existing secondary data and primary data generated during the study. Every pair mother-child which had all information considered in the inclusion criteria were “included or recruited”. In case women had more than one child, every child that fulfilled inclusion criteria was considered for a different pair. There were cases of women treated that had children before and after trypanocidal treatment, and so formed part of pairs in both groups.

The information was included in a specifically tailored form with an encrypted identification number to protect the patient’s identity. In the mothers’ form, the following variables were considered: a) life history of the mother (genealogical data, migration history, medical history, obstetric history); b) infection with T. cruzi (way of discovery, serological tests, follow-up studies of infection); c) etiological treatment (whether she received it or not, date, type of drug, dose and time, tolerance level, post-treatment controls using serology with quality control); d) clinical course (clinical and electrocardiography examination). In the children’s form variables were collected on: a) life history of the child (genealogical data, migration, transfusion and living conditions history, period of gestation and birth, medical history at birth); b) infection by T. cruzi (age at diagnosis, serological and/or parasitological tests).

The information was gathered always by the same specifically trained medical and/or biochemistry professionals, as appropriate.

Subsequently, each paper form with all the information of the mother and her child was uploaded to an on-line database generated “ad hoc”.

Data analysis

For data analysis, we used the STATA software, version 9.0. To identify potential confounders, we analyzed distribution in both treated and not treated women, of variables such as maternal age, migration history, socioeconomic status, and level of education collected as epidemiological data from the MR.

The comparison of proportions was performed using a Fisher exact test or \( \chi^2 \) as appropriate, and for comparing the means, we used Student’s t test or the Bonferroni test. The difference in time was due to different recommendations considered in national protocols in different periods and interruptions. Treatment with benznidazole consisted of a media dose of 5.16 mg/kg/day (DS 0.47, range 4.13–6.35) during 15–66 days (media 45±14). There were five cases of less than 30 days of treatment (15, 17, 25, 27 and 28 days). Variation in days occurred due to different medical criteria and/or interruption. Tolerance was good for 86.3% (57/67) of women treated with benznidazole and 62.5% (10/16) of those treated with nifurtimox. Some of them had more than one antecedent. Figure 2 shows how the discovery of the infection with T. cruzi occurred in the mothers studied.

Regarding etiological treatment 72 women were treated with benznidazole, 16 women treated with nifurtimox, and 56 women did not receive treatment. Treatment with benznidazole consisted of a media dose of 5.16 mg/kg/day (DS 0.47, range 4.13–6.35) during 15–66 days (media 45±14). There were five cases of less than 30 days of treatment (15, 17, 25, 27 and 28 days). Variation in days occurred due to different medical criteria and/or interruption. Tolerance was good for 86.3% (57/72) of women treated with benznidazol and 62.5% (10/16) of those treated with nifurtimox. One woman treated with nifurtimox (6.2%) and one treated with benznidazol (1.4%) had bad tolerance, which forced them to discontinue the medication. Side effects for treatment with benznidazole were rashes, pruritus, and/or edema 20.8% (15/72). Among women treated with nifurtimox, the most common side effects were gastrointestinal disorder, 37.5% (6/16).

Results

One thousand and 527 clinical records of infected women were screened, of which 144 mothers were included and made up 354 pairs with their biological children. Reasons for exclusion were: a) the woman did not had any child, b) it wasn’t possible to establish contact with the woman to figure out whether she had or not any child and/or to complete information of transfections and residence of the child, c) the woman had children but they didn’t have information on the child’s diagnosis and they did not attend to the center to test the child (one or several). Of the included pairs, 132 were made-up with women who had received trypanocidal treatment prior to being mothers and 222 pairs with women who were not treated (Figure 1).

The geographical origin of the 144 mothers enrolled was as follows: 85% from Argentina; 10% from Bolivia, 4% from Paraguay, and 1% from Uruguay (Table 1). Of the Argentine women, 33% were born and/or lived until 15 years in areas of high or moderate risk for vectorial transmission and 52% lived in houses of precarious conditions, but at the moment of birth of their children only 8% live in those places and 92% lived in areas of low risk or without risk (non-endemic) areas for vectorial transmission and in houses with urban characteristics. No significance difference was observed between the groups of treated and non-treated women. The probable route of infection in these women were: 66% (95/144) was born and/or lived in area of high risk of vectorial transmission and 52% lived in houses of precarious conditions, but at the moment of birth of their children only 8% live in those places and 92% lived in areas of low risk or without risk (non-endemic) areas for vectorial transmission and in houses with urban characteristics. No significance difference was observed between the groups of treated and non-treated women. The probable route of infection in these women were: 66% (95/144) was born and/or lived in area of high risk of vectorial infection, 23% (33/144) received transions and 31% (45/144) had a history of a mother infected with T. cruzi. Some of them had more than one antecedent. Figure 2 shows how the discovery of the infection with T. cruzi occurred in the mothers studied.
The 56 non-treated women had 222 children, of which 45 (20.3%) were confirmed infected with *T. cruzi*. Of these, 11 children had a history of having lived in regions where they were likely to be infected through vectorial transmission (migration history); therefore, there is no certainty that the infection route was congenital transmission. The remaining 34 children (15.3%) presented positive maternal serology as the only antecedent, not having received blood transfusions or resided in areas at risk of vectorial infection. From the group of 34 congenitally infected children, in five cases confirmatory diagnosis was made by...
visualization of the parasite through xenodiagnosis or strout method before their first year, and the rest were diagnosed by positive serology after 10 months of age. The average age of diagnosis was 5.8 years (SD 5.6, range 0.1–19.9 years).

Of the 132 children born to the 88 women who had been treated before pregnancy, none had infection with *T. cruzi*. Five of them came from two mothers with incomplete treatment. The diagnosis was made at an average age of 4.8 years (SD 4.4; range 0.8 to 20.0). If we assumed one positive case in the treated group, the risk of the occurrence of congenital transmission in treated mothers was 25 times lower compared to those untreated before pregnancy (Relative Risk, RR = 0.04, CI:95%: 0.012 to 0.166; p<0.05).

The gestational age and mode of delivery did not differ between the children of treated and untreated mothers, nor between healthy newborns and newborns with congenital infection (p>0.05, Fisher exact test). The birth weight of the children was similar regarding treatment in mothers and status of infection in the newborn (Student’s t-test, p>0.05) (Table 2).

The average age of mothers at childbirth was 26.6 ± 6.5 years and 25.4 ± 6.2 years for treated and untreated mothers, respectively. We found no differences when comparing the age of mothers at childbirth, by parity, the occurrence of congenital infection, and having received treatment (Bonferroni p>0.05).

Table 3 describes the population of studied mothers grouped by age and time of follow-up. For the analysis of the serological and clinical evolution (SCE) of mothers untreated and treated with trypanocidal drugs, we selected 117 mothers (71 mothers treated, and 46 mothers untreated) out of 144 that made up the pairs, with a follow-up equal to or greater than 8 years.

The following groups were formed according to age and treatment: A) 25 women who were treated up to 15 years of age (23 treated with benznidazole and 2 with nifurtimox); B) 46 women treated after 15 years of age (33 with benznidazole and 13 with nifurtimox); C) 46 untreated women over 15 years old.

The average ages at the time of treatment or start of follow-up were: group A) 9.97 ± 2.74 years; B) 27.9 ± 6.7 years; C), 29.2 ± 6.2 years.

The average follow-up times were 16.3 ± 5.8, 17.5 ± 9.2 and 18.6 ± 8.6 years for groups A, B and C, respectively.

Serological evolution

**Group A.** Sixteen out 25 women (64%) had negative serology after an average time of 17.5 years; 4 out of 25 (16%) had a discordant final serology status (weak reactivity at the cut-off for any of the serological tests and non-reactivity in another), with an average follow-up of 13.3 years. The remaining 20% (5/25) of treated women remained with reactive serology until the last control and were followed for 14.7 years on average.

**Group B.** Fifteen out of 46 (32.6%) had negative serology after an average time of 24.2 years; 6/46 (13%) had a discordant final serology status, with average follow-up of 23.6 years. 54.4% (25/46) of the treated women remained with reactive serology until the last control, followed for 12 years on average.

**Group C.** 2/46 (4.4%) showed fluctuations during the follow-up, with discordant final serology, while 44/46 (95.6%) remained with reactive serology without significant changes in serologic titers for an average 18.6 years.

Sero-negativization was observed in treated women and not in untreated ones (Figure 3). This phenomenon was observed after 10 years of follow-up (p = 0.0001 log-rank test). There were differences when analyzing the probability of negative seroconversion according to the age at which the mother received treatment (group A vs. group B). Women who were treated before or at 15 years of age presented earlier negativization, compared to those treated at ages higher than 15 years. For those women treated at age of 15 years old or earlier (A), they reached a 50% probability of seronegativization at 15 years of follow-up, meanwhile those treated between 16 to 45 (B) reached 50% probability of seroconversion only at 26 years of follow-up (p = 0.0004, log-rank test) (Figure 4).

Clinical progression

The ECG alterations compatible with CCC presented by the mothers with follow-up are shown in Table 4. No alterations suggestive of CCC were observed in treated women of group A (0/25), and in group B only one woman modified her clinical status 1/46 (2.2%), developing LAFB and IVE during follow-up at the age of 48 years. Two other women (01-144-00 and 02-048-00) that presented ECG alterations during the study had also associated pathologies and therefore it was no possible to establish causality of these alterations to Chagas disease.
Among the women who remained untreated (group C), 7/46 (15.2%) became ill with alterations attributable to CCC. There were significant differences in clinical progression between treated and untreated women of ages older than 15 years (p<0.05, Fisher exact test; Relative Risk, RR = 0.14, CI:95%: 0.02 to 0.80).

Discussion

There was no case of congenital transmission among the children born to mothers that received treatment before pregnancy, whereas in the group of children from non treated mothers there were 34 cases (15.3%). This finding supports the hypothesis of a protective effect of trypanocidal treatment before pregnancy for preventing congenital transmission, and a risk for transmission of T. cruzi in newborn from treated mothers of 25 times lower (assuming one case of transmission in the treated group). The rate of congenital transmission found in the non treated group is high compared to the average rate of 4.7% (CI95%: 3.9 to 5.6%) [5], although other studies have found higher numbers; for example, 11% by Rissio AM and colleagues [16] in a non endemic area and 17% by Sosa-Estani S and colleagues [17] in an endemic area. However this endemic area (Gran Chaco Region) was sprayed, it had a recent risk for vectorial transmission which might increase congenital transmission rate since these mothers have probably higher parasite burden due to probable repetitive infections [17–20]. Although the residence area of the study population was urban areas or areas under surveillance, our study did not assessed parasitic load in mothers to explain this potential phenomenon where the risk of re-infections could determine high parasitemias. These variations in vertical transmission rates could be attributed to differences in the methodology and the techniques used for diagnosis and when the control of the children is done. Other factors that may have an impact are the parasite load in the mother and/or the strain of T. cruzi, and the immunological and/or nutritional status of pregnant women, although none has been conclusively demonstrated [19].

Besides these considerations, we could have overestimated the detected cases of congenital Chagas due to a possible “memory” bias in infected subjects that had a late diagnosis (average age of children at diagnosis: 5.8 years). Although we excluded those who had traveled or lived in areas at risk of vectorial infection, we could have included some cases of vectorial infection or of infection by a route other than congenital, as the information was obtained from the answers given by the mothers in personal interviews. This method of data collection was applied to the entire study population.

While not all women infected with T. cruzi transmitted the infection to their children, the cases of congenital Chagas disease only occurred in infants born to mothers who had not received specific deparasitation treatment. It was shown that the relative risk of transmitting the infection is 25 times higher for untreated mothers than for those who received treatment before pregnancy. It was thus showed that etiological treatment is useful to prevent congenital infection by T. cruzi, corroborating the results of a preliminary investigation [12].

The scheme of treatment (drug, dose, duration) that had been applied to the treated mothers was according the official guidelines of care of patients infected with T. cruzi in Argentina [21]. These guidelines recommend treatment by 60 days but, consider an acceptable scheme 30 days of treatment when any justified reason does not allow completing the treatment.

No differences were found between children born infected and uninfected regarding birth weight, gestational age and mode of delivery.
delivery. The mother’s age at childbirth had also no influence. This corroborates the lack of a relevant clinical expression of symptoms and/or signs that characterize most newborns with congenital Chagas disease, and the vital need to actively look for them.

The children with congenital infection who were diagnosed after one year of age (average age of 5.8 years) confirm the deficiency of the health system in making an early diagnosis. The need to expand the coverage of early diagnosis is also shown by the 16% of mothers who became aware of their infected condition during pregnancy, and the 11% with serological controls at school age.

When assessing the evolution of conventional serology titers in the mothers studied, we observed negativization only in those who had received trypanocidal treatment, in a 43.7% (31/71). This percentage could be enlarged in the coming years by the 14.1% (10/71) with discordant serology at the last control. This presumption is based on the fact that those who became negative had a slightly higher average follow-up time.

The age at which the infected patient received treatment is important, as significant differences in the probability and time of negative seroconversion were observed between women treated before and after 15 years of age. The negative seroconversion rates observed when treatment was administered at a later age are also noteworthy, even though more time was required.

In conjunction with these serological results, we observed a better clinical course in women who received trypanocidal treatment compared with those who were not treated. These results are consistent with those observed by other investigations or reviews and by our group [22–27].

There were some limitations and potential biases. There could be a selection bias because the population sample was selected by convenience sampling not randomly or probabilistically, as was mentioned above. The measurement of the degree of adherence and compliance with the treatment performed on an outpatient basis was not recorded by direct observation, using instead what was expressed by the patient and was reported in the MR. There might have been potential recall biases, but the answers given by

### Table 3. Distribution of 117 women with chronic infection of *T. cruzi*, treated and untreated with nifurtimox or benznidazole, by age group and time of follow-up equal to or greater than 8 years, Argentina.

| Age Group * | TREATED | NON-TREATED |
|-------------|---------|-------------|
|             | N according to Drug | Follow-up Time (years ± Sd) | N | Follow-up Time (years ± Sd) |
|             | Nifurtimox | Beznidazol | Nifurtimox | Beznidazol |
| ≥15         | 2 | 23 | 16.3±5.8 | 0 | - |
| 16–25       | 2 | 16 | 16.1±9.2 | 11 | 22.8±7 |
| 26–35       | 9 | 13 | 18.5±10 | 25 | 16.5±8.2 |
| >35         | 2 | 4 | 18.1±6.1 | 10 | 19.4±10.1 |
| Total       | 15 | 56 | 17.1±8.1 | 46 | 18.6±8.6 |

Figure 3. Kaplan-Meier curve showing serological reactivity rate during follow-up among 117 treated and untreated women. doi:10.1371/journal.pntd.0003312.g003
the patient in the personal interview were considered acceptable, as was the criterion of the professional that recorded the information. Currently, the specific antiparasitic treatment must be mandatorily administered in all cases of acute infection because its effectiveness at this stage is close to 100%; also in cases of chronically infected

Table 4. Evolution of electrocardiographic alterations compatible with chronic Chagas cardiomyopathy (CCC) that appeared during follow-up in women treated and untreated with trypanocides, Argentina.

| ID     | Age (years) | Alt ECG | Assoc Patolog | Age (years) * | Alt ECG | Assoc Patolog |
|--------|------------|---------|---------------|---------------|---------|---------------|
| 01-144-00 | 30         | Normal  | No            | 54            | LAFB    | AHT = age     |
| 01-351-00 | 25         | Normal  | No            | 48            | LAFB + fVE | No           |
| 02-048-00 | 34         | Normal  | No            | 40            | Sinus bradycardia | WPW syndrome |

| ID     | Age (years) | Alt ECG | Assoc Patolog | Age (years) * | Alt ECG | Assoc Patolog |
|--------|------------|---------|---------------|---------------|---------|---------------|
| 01-213-00 | 19         | Normal  | No            | 42            | fVE     | No            |
| 01-262-00 | 30         | Normal  | No            | 49            | LAFB    | No            |
| 01-365-00 | 23         | Normal  | No            | 45            | RBBB    | No            |
| 01-362-00 | 31         | Normal  | No            | 40            | LAFB    | No            |
| 01-356-00 | 25         | Normal  | No            | 48            | RBBB + LAFB | No         |
| 01-366-00 | 29         | Normal  | No            | 37            | LAFB    | No            |
| 02-031-00 | 37         | Normal  | No            | 42            | LAFB    | No            |

*Age at start of ECG alterations.

Wolf-Parkinson-White Syndrome.

RBBB: Complete Right Bundle-Branch Block.

LAFB: Left Anterior Fascicular Block.

fVE: Frequent Ventricular Extrasystoles.

AHT: Arterial Hypertension.

doi:10.1371/journal.pntd.0003312.t004
persons less than 19 years of age and in cases of reactivation by immunosuppression at any age [21]. Trypanocidal treatment could also be offered to adults with chronic infection by *T. cruzi* [21].

These results add evidence about the benefit of providing etiological treatment to young people with chronic infection. Since the treatment prolongs its effectiveness in reducing the risk of mother to child transmission, it would be an efficient practice for the reduction or complete prevention of new cases of congenital infection with *T. cruzi* in both rural and urban centers.

Furthermore its importance as a form of primary prevention to reduce or prevent new cases of congenital Chagas disease, the recommendation of indicating trypanocidal treatment would also serve as a secondary prevention mechanism due to the protective effect observed during the clinical course. By eliminating or reducing at least 43.7% of the parasite load, the risks of morbidity and mortality of the infection would decrease significantly. This would lead to a decrease in the burden of the disease by reducing public health costs and preventing the economic and social impact produced by the deterioration of the quality of life of infected people; the expense in heart disease drugs, pacemakers, defibrillators, transplants, etc. caused by the symptomatic treatment of the chronic phase would decrease too [28–29].

Despite the promise offered by these results, it would be useful to extend the study population. Participation of other institutions that take care of patients chronically infected with *T. cruzi* would help to define with more certainty the most appropriate therapy and prophylaxis for these patients.

**References**

1. Zaidenberg M, Spillmann C, Carrion Pizc R, (2004) Control de Chagas en la Argentina. Su evolución. Rev Argent Cardiol 72: 375–380.

2. Yadon Z and Schmunis G (2009) Congenital Chagas disease: estimating the potential risk in the United States. Am J Trop Med Hyg 81(6): 927–933.

3. Bratus L, Schneider D, Postigo J, Delgado W, Mollinedo S, et al. (2007) Evidence of congenital transmission of *Trypanosoma cruzi* in a vector-free area of Bolivia. Trans R Soc Trop Med Hyg 101: 1159–1160.

4. De Rissio AM, Riarte AR, Garcia MM, Esteve MI, Quaglino M, et al. (2010) Congenital *Trypanosoma cruzi* infection. Efficacy of its monitoring in an urban reference health center in a non-endemic area of Argentina. Am J Trop Med Hyg 82(5): 830–845.

5. Howard EJ, Xiong X, Carlier Y, Sosa-Estani S, Buekens P. (2013) Frequency of the congenital transmission of *Trypanosoma cruzi*: a systematic review and meta-analysis www.bjog.org DOI 10.1111/1471-0528.12396: BJOG.

6. Sosa-Estani S (2005) Congenital transmission of *Trypanosoma cruzi* in Argentina. Rev Soc Bras Trop Med 38(2): 29–32.

7. Basuneho MA, Paes JR, Segura E, Marro O, Sanchez Negrete J, et al. (1999) Transmission del la enfermedad de Chagas en Salta y la detección de casos congénitos Medicina (Buenos Aires) 59(2): 141–146.

8. Gurreri RE, Segura EL, Cohena JE. (2003) Congenital transmission of *Trypanosoma cruzi* infection in Argentina. Emerg Infect Dis 9(1): 29–32.

9. Streiger M, Fabbro D, del Barco M, Beltranino R, Bovero N. (1995) Chagas congénito en la Ciudad de Santa Fe. Diagnóstico y tratamiento. Medicina (Buenos Aires) 53: 125–33.

10. Moya PR, Paolasso R, Blanco L, Lapasset M, Samantcano C, et al. (1985) Tratamiento de la enfermedad de Chagas con nitirimox durante los primeros meses de vida. Medicina (Buenos Aires) 45: 533–538.

11. Blanco SB, Segura EL, Curia EN, Chinti R, Tulian L, Flores I, et al. (2000) Congenital transmission of *Trypanosoma cruzi*: an operational outline for detecting and treating infected infants in north-western Argentina. Trop Med Int Health 5(4): 293–301.

12. Sosa-Estani S, Curia E, Velazquez E, Yampotis C, Segura E. (2009) Etiological treatment of young women infected with *Trypanosoma cruzi*, and prevention of congenital transmission. Rev Soc Bras Trop Med 42(5): 484–487.

13. Sosa-Estani S, Curia E, Velazquez E, Yampotis C, Segura E. (2009) Etiological treatment of young women infected with *Trypanosoma cruzi*, and prevention of congenital transmission. Rev Soc Bras Trop Med 42(5): 484–487.

14. Bisio M, Altcheh J, Lattner J, Moscatelli G, Fink V, et al. (2013) Benzimidazoles, treatment of chagasic encephalitis in pregnant women with AIDS. Emerg Infect Dis 19(9): 1490–2. doi:10.3201/eid1909.130667.

15. Correa VR, Barbosa FG, de Melo Junior CA, D’Albuquerque e Castro LF, de Andrade Junior HF, et al. (2014) Uneventful benzimidazole treatment of acute Chagas disease during pregnancy: a case report. Rev Soc Bras Trop Med 47(3): 397–400.

16. Rissio AM de, Scifo K, Cardoni R. (2009) La transmission madre-hijo del *Trypanosoma cruzi* en la Argentina. Medicina (Buenos Aires) 69: 529–535.

17. Sosa-Estani, Dri L, Touris C, Abalde S, Dell’arciprete A, et al. (2009) Transmisión vectorial y congénita del *Trypanosoma cruzi* en las Lomitas, Formosa. Medicina Buenos Aires 69: 424–430.

18. Hermann E T, Truyen C, Vega C, Even J, Rodriguez P, et al. (2004) Congenital transmission of *Trypanosoma cruzi* is associated with maternal enhanced parasitemia and decreased production of interferon gamma in response to parasite antigens. J Infect Dis. 189: 1274–1281.

19. Brutos L, Castillo H, Bernal C, Salas NA, Schneider D, et al (2010) Short Report: Detectable *Trypanosoma cruzi* parasitemia during pregnancy and delivery as a risk factor for congenital Chagas disease. Am J Trop Med Hyg, 83: 1044–47.

20. Bia J, Volta B, Velazquez EB, Ruiz AM, Rissio AM, et al (2012) Vertical transmission of *Trypanosoma cruzi* infection: quantification of parasite burden in mothers and their children by parasite DNA amplification. Trans R Soc Trop Med Hyg. 106(10): 625–8.

21. Ministerio de Salud de la Nación.(2012) Guía para la atención del paciente infectado con *Trypanosoma cruzi* (enfermedad de Chagas). Argentina. Agosto 2012.

22. Viotti R, Vigliano C, Armenti H, Segura E. (1994) Treatment of chronic Chagas disease with benzimidazole: clinical and serologic evolution of patients with long term follow-up. Am Heart J. 127: 151–162.

23. Visti R, Vigliano C, Lecoco B, Bertocchi G, Petri M, et al. (2006) Long-term cardiac outcomes of treating chronic Chagas disease with benzimidazole versus no treatment. Ann Intern Med 144: 724–734.

24. Fernandes CD, Tischer FM, Balbino MM, Liarte DB, Scholl D, et al. (2009) Efficacy of benzimidazole treatment for asymptomatic chagasic patients from state of Rio Grande do Sul evaluated during a three years follow-up. Mem Inst Oswaldo Cruz 104(1): 27–32.

25. Fabbro D, Streiger M, Arias E, Biza M, del Barco M, et al. (2007) Trypanocidal treatment among adults with chronic Chagas disease living in Santa Fe city (Argentina) over a mean follow-up of 21 years: parasitological, serological and clinical evolution. Rev Soc Bras Med Trop 40: 1–10.

26. Fabbrro de Suasaualbar D, Arias E, Streiger M, Picenza M, Ingaramo M, et al. (2000) Evidential behavior towards cardiacmyopathy of treated (nifurtimox or benznidazole) and untreated chronic chagasic patients. Rev Inst Med Trop Sao Paulo 42: 99–109.

27. Sosa-Estani S, Visti R, Segura EL. (2009) Therapy, diagnosis and prognosis of chronic Chagas disease: insight gained in Argentina. Mem Inst Oswaldo Cruz. 04 Suppl 1: 167–80.

28. Bern C, Montgomery SP. An estimate of the burden of Chagas disease in the United States. Clin Infect Dis. 49:52–549 2009.

29. Lee BY; Bacon KM, Bottazzi ME, Hotez PJ. (2013) Global economic burden of Chagas disease: a computational simulation model. Lancet Infect Dis. 13(4): 542–6.

**Supporting Information**

**Checklist S1 STROBE checklist.** (DOC)

**Acknowledgments**

To the professors-researchers of the National Center on Domestic Endemics (CIEN): Enrique Arias, Maria Laura Bizai for his joint work in the clinical, serological and parasitological follow-up of patients.

To the Department of Diagnostics, and the Department of Clinic, Pathology and Treatment of Instituto Nacional de Parasitología (ENP) “Dr. Mario Fatale Chaben”, especially to physicians Adelina Riarte, Dr. Gonzalo Tomás, the biochemists Karenima Scollo and bachelor Claudio Invernizzi for their valuable collaboration. We also thank Dr. Elizabeth Howard, and Dr. Pierre Buckens for your critical review and helpful comments.

Sergio Sosa-Estani is a member of the Carrera del Investigador Científico, from the Consejo Nacional de Investigaciones Científicas y Técnicas de Argentina (CONICET).

**Author Contributions**

Conceived and designed the experiments: DLF SSE ED VO. Performed the experiments: ED VO MOC CH MS. Analyzed the data: DLF SSE ED VO MOC SD. Contributed reagents/materials/analysis tools: DLF. Wrote the paper: DLF SSE ED VO.

PLOS Neglected Tropical Diseases  |  www.plosntds.org  |   November 2014  |   Volume 8  |   Issue 11  |   e3312